lansoprazole has been researched along with Sleep Wake Disorders in 4 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Sleep Wake Disorders: Abnormal sleep-wake schedule or pattern associated with the CIRCADIAN RHYTHM which affect the length, timing, and/or rigidity of the sleep-wake cycle relative to the day-night cycle.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients (N=305) with frequent, moderate-to-very severe nocturnal heartburn and associated sleep disturbances were randomized 1:1 in a double-blind fashion to receive dexlansoprazole MR or placebo once daily for 4 weeks." | 9.15 | The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. ( Fass, R; Han, C; Johnson, DA; Mody, R; Orr, WC; Perez, MC; Pilmer, BL; Stern, KN, 2011) |
| "Patients (N=305) with frequent, moderate-to-very severe nocturnal heartburn and associated sleep disturbances were randomized 1:1 in a double-blind fashion to receive dexlansoprazole MR or placebo once daily for 4 weeks." | 5.15 | The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. ( Fass, R; Han, C; Johnson, DA; Mody, R; Orr, WC; Perez, MC; Pilmer, BL; Stern, KN, 2011) |
| "Global rates of obesity and type 2 diabetes mellitus (T2DM) are increasing globally concomitant with a rising prevalence of sleep deprivation and sleep disorders." | 2.72 | The links between sleep duration, obesity and type 2 diabetes mellitus. ( Antza, C; Kostopoulos, G; Mostafa, S; Nirantharakumar, K; Tahrani, A, 2021) |
| "The consequences of nocturnal gastroesophageal reflux disease (GERD) may be greater than daytime GERD in terms of clinical complications such as increased risk of esophageal lesions and respiratory conditions, as well as issues of health-related quality of life, sleep, work productivity, and economics." | 2.44 | Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies. ( Johnson, DA; Katz, PO, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antza, C | 1 |
| Kostopoulos, G | 1 |
| Mostafa, S | 1 |
| Nirantharakumar, K | 1 |
| Tahrani, A | 1 |
| Johnson, DA | 2 |
| Katz, PO | 1 |
| Fass, R | 1 |
| Orr, WC | 1 |
| Han, C | 1 |
| Mody, R | 1 |
| Stern, KN | 1 |
| Pilmer, BL | 1 |
| Perez, MC | 1 |
| Huuhka, K | 1 |
| Riutta, A | 1 |
| Haataja, R | 1 |
| Ylitalo, P | 1 |
| Leinonen, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study[NCT04028466] | Phase 4 | 82 participants (Actual) | Interventional | 2019-05-26 | Terminated (stopped due to Budget for the study was withdrawn and discontinued) | ||
| An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan[NCT03079050] | Phase 4 | 33 participants (Actual) | Interventional | 2017-02-27 | Completed | ||
| A Phase 3 Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy of TAK-390MR (30 mg QD) Compared to Placebo on Relief of Nocturnal Heartburn in Subjects With Symptomatic Gastroesophageal Reflux Disease (G[NCT00627016] | Phase 3 | 305 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage calculated by the number of heartburn-free nights out of the total number of nights during the treatment period with a diary entry indicating presence or absence of nighttime heartburn in subjects who had ≥1 diary entry indicating presence or absence of nighttime heartburn, as indicated by the subject's daily diary. Subjects indicate the presence (Yes/No) of nocturnal heartburn symptoms in a Daily Electronic Diary. Nights missing diary results were excluded from the numerator and denominator. (NCT00627016)
Timeframe: 4 Weeks
| Intervention | Percentage of nights (Median) |
|---|---|
| Placebo | 35.7 |
| Dexlansoprazole 30 mg QD | 73.1 |
Relief of nighttime heartburn was defined as 6 of 7 nights with no heartburn and at most 1 night with mild heartburn; lack of relief of nighttime heartburn was defined as 2 or more out of 7 nights with heartburn, or 1 night with at least moderate heartburn. Subjects indicate the presence and severity (mild, moderate, severe, or very severe) of nocturnal heartburn in a Daily Electronic Diary. The percentage was calculated as the number of subjects with relief of nighttime heartburn divided by the number of subjects whose relief status could be determined. (NCT00627016)
Timeframe: Last 7 days of treatment
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 19.6 |
| Dexlansoprazole 30 mg QD | 47.5 |
Relief of GERD-associated sleep disturbance was defined as 6 of 7 nights with no GERD associated sleep disturbances; lack of relief of GERD-associated sleep disturbance was defined as 2 or more out of 7 nights with GERD-associated sleep disturbance. Subjects indicate the presence (Yes/No) of GERD associated sleep disturbance in a Daily Electronic Diary. The percentage was calculated as the number of subjects with relief of GERD-associated sleep disturbance divided by the number of subjects whose relief status could be determined. (NCT00627016)
Timeframe: Last 7 days of treatment
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 47.9 |
| Dexlansoprazole 30 mg QD | 69.7 |
2 reviews available for lansoprazole and Sleep Wake Disorders
| Article | Year |
|---|---|
The links between sleep duration, obesity and type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Lansoprazole; Life Style; Obesity; Risk Facto | 2021 |
Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; O | 2008 |
2 trials available for lansoprazole and Sleep Wake Disorders
| Article | Year |
|---|---|
The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Double-Bli | 2011 |
The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Double-Bli | 2011 |
The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Double-Bli | 2011 |
The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Double-Bli | 2011 |
The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: A randomized, double-blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anticonvulsants; Antidepressive Ag | 2006 |